{"meshTagsMajor":["Drug Resistance, Neoplasm"],"meshTags":["Drug Resistance, Neoplasm","Protein Kinase Inhibitors","Humans","Melanoma","RNA Interference","Mutation","Receptor, Epidermal Growth Factor","SOXE Transcription Factors","RNA, Small Interfering","Antineoplastic Agents","Indoles","Sulfonamides","Phenotype","Proto-Oncogene Proteins B-raf","Microphthalmia-Associated Transcription Factor"],"meshMinor":["Protein Kinase Inhibitors","Humans","Melanoma","RNA Interference","Mutation","Receptor, Epidermal Growth Factor","SOXE Transcription Factors","RNA, Small Interfering","Antineoplastic Agents","Indoles","Sulfonamides","Phenotype","Proto-Oncogene Proteins B-raf","Microphthalmia-Associated Transcription Factor"],"genes":["SOX10"],"publicationTypes":["Journal Article"],"abstract":"Slow-cycling BRAF melanoma cells are notoriously resistant to standard chemotherapy or targeted therapy but the underlying mechanism remains elusive. Now a new study unlocks this mystery and offers novel insights into developing more effective therapeutic interventions. ","title":"Linking SOX10 to a slow-growth resistance phenotype.","pubmedId":"24853952"}